NKTX — Nkarta, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1787400 ·
Last close
$1.25
Market Cap
$89.53M
52W High
$3.72
52W Low
$1.11
ADV30
1,463,534
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -35,777,000 | -33,326,000 | 308,461,000 | 48,354,000 | 92,712,000 |
| Jun 2026 | 0 | — | -43,128,000 | -40,368,000 | 337,645,000 | 24,958,000 | 89,907,000 |
| Mar 2026 | 0 | — | -30,876,000 | -27,832,000 | 372,073,000 | 27,356,000 | 86,213,000 |
| Dec 2025 | 0 | — | -30,961,000 | -27,409,000 | 404,209,000 | 39,634,000 | 91,884,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-92,756,000
Investing CF
$63,554,000
Financing CF
$746,000
CapEx
$-1,294,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.57
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-716,508,000
Inventory
—
Receivables
—
ST Investments
$157,806,000
EBIT TTM
$-132,251,000
Pretax Income TTM
$-117,324,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -121,997,000 | -104,084,000 | 404,209,000 | 91,884,000 | 312,325,000 | -88,699,000 |
| Dec 2024 | 0 | -128,194,000 | -108,790,000 | 501,203,000 | 93,227,000 | 407,976,000 | -99,696,000 |
| Dec 2023 | 0 | -131,650,000 | -117,501,000 | 378,885,000 | 105,600,000 | 273,285,000 | -86,160,000 |
| Dec 2022 | 0 | -118,955,000 | -113,837,000 | 472,938,000 | 100,731,000 | 372,207,000 | -57,000,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-117,324,000
OpCashFlow TTM
—
Assets (Latest)
$337,645,000
Forward EPS
$-1.42
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HURA | TuHURA Biosciences, Inc./NV | $89.22M | $1.40 | — |
| GNLX | GENELUX Corp | $90.49M | $2.00 | — |
| PMVP | PMV Pharmaceuticals, Inc. | $92.15M | $1.22 | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $86.96M | $5.80 | — |
| RVRC | Revium Rx. | $86.84M | $1.43 | — |
News headlines (Yahoo Finance, 1h cache)
Allogeneic Cell Therapy - Global Strategic Business Report 2026: Capitalize on 27.7% CAGR to Capture $2.4B by 2032 with Allogene, Gilead Sciences, Atara and Nkarta
2026-11-17 14:53 · Yahoo
Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026
2026-11-11 12:00 · Yahoo
Nkarta Reports Initial NKX019 Clinical Responses in Myositis and Systemic Sclerosis Trials
2026-11-09 13:28 · Yahoo
Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
2026-11-06 21:01 · Yahoo
Nkarta to Participate in September Investor Conferences
2026-09-10 11:00 · Yahoo
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
2026-09-08 11:00 · Yahoo
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-08-10 20:24 · Yahoo
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-26 12:45 · Yahoo
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-12 20:01 · Yahoo
Nkarta to Participate in Needham Virtual Healthcare Conference
2026-04-09 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.